Abstract
Breast cancer is a public health problem due to its high frequency. The cancerisation process is characterized in part by the dysfunction of cellular communication pathway, like on one implicating Her-2. Her-2 is overexpressed by 30% in breast cancer and is associated with poor prognosis, with a decrease overall survival and a shortening time to disease progression. The Her-2/neu oncogene is involved in the development of breast cancer by amplification and/or overexpression of its product, the Her-2 protein that takes a considerable importance as a potential therapeutic target with specific antitumoral therapies. Besides, more and more studies demonstrated the relevance of Her-2 serum level as a predictive marker in the setting of metastatic breast cancer overexpressing Her-2.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
